Bristol Myers (BMY) Earnings Date & Reports 8,681 Followers Portfolio Earnings Data Report Date Apr 27, 2023 Before Open Not Confirmed Period Ending 2023 (Q1) Consensus EPS Forecast $1.98 Last Year's EPS $1.96 Same Quarter Last Year Analyst Consensus Moderate Buy Based on 9 Analysts Ratings Bristol Myers (BMY) Earnings, Revenues Date & History Whether its bringing more than a dozen key medicines to market since 2009, or expanding patient access to medicine, our commitment to patients inspires us and guides our actions as responsible corporate citizens. Repotrectinib, which is being studied in a registrational Phase 2 study in adults and a Phase 1/2 study in pediatric patients, has shown antitumor activity and durable responses among kinase inhibitor treatment-nave and pre-treated patients. When adjusted for foreign exchange impact, international revenues increased 7%. Print. All comparisons are made versus the same period in 2020 unless otherwise stated. With your consent, we may also use third party cookies to analyze your usage of the website. There will be a conference call on February 4, 2022 at 8 a.m. they used to have flexible schedules- though that is unfortunately being phased out. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram. Written by Zacks Equity Research for Zacks ->. In addition to the offer to purchase, the related letter of transmittal and certain other offer documents, as well as the solicitation/recommendation statement, the company and Turning Point Therapeutics file annual, quarterly and special reports, proxy statements and other information with the SEC. 0000004547 00000 n 0000008852 00000 n 0000192879 00000 n Forward-looking statements contained on this website should be evaluated together with the many uncertainties that affect Bristol Myers Squibb's business, particularly those identified in the cautionary factors discussion in the companys most recent annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. Bristol Myers Squibb Company BMY announced that the Committee for Medicinal Products Holiday Calendar; Repligens earnings estimates for 2021 Bristol Myers Squibbs 1Q Results Miss Estimates; Street Says Buy. Because the non-GAAP financial measures are not calculated in accordance with GAAP, they should not be considered superior to or as a substitute for the related financial measures that are prepared in accordance with GAAP and are not intended to be considered in isolation and may not be the same as or comparable to similarly titled measures presented by other companies due to possible differences in method and in the items being adjusted. In discussing financial results and guidance, the company refers to financial measures that are not in accordance with U.S. Generally Accepted Accounting Principles (GAAP). Play. The Bristol-Myers Squibb Benefits Program gives you the flexibility and opportunity to choose from a variety of options. This was driven by its aforementioned revenue growth, a 330-basis-point. Join scientists like Aparna's team, who have helped Bristol Myers Squibb establish a leadership position within hematology oncology therapies, doing interesting and meaningful work while transforming patients lives daily. Whether recruiting from academia or the commercial biopharma sector, Mihaela explains why a move to BMS is a great career move. Forward-looking statements are based on current expectations and projections about the companys future financial results, goals, plans and objectives and involve inherent risks, assumptions and uncertainties, including internal or external factors that could delay, divert or change any of them in the next several years, that are difficult to predict, may be beyond the companys control and could cause the companys future financial results, goals, plans and objectives to differ materially from those expressed in, or implied by, the statements. Bristol-Myers Squibb is a multinational pharmaceutical company headquartered in New York City. **Included as part of the new product portfolio 0000013014 00000 n Forward-looking statements contained on this website should be evaluated together with the many uncertainties that affect Bristol Myers Squibb's business, particularly those identified in the cautionary factors discussion in the companys most recent annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. Also note that a reconciliation of the forward-looking revenue (ex-FX), free cash flow and non-GAAP operating margin measures is not provided due to the inherent difficulty in forecasting and quantifying items that are necessary for such reconciliation. Glassdoor is your resource for information about the Vacation & Paid Time Off benefits at Bristol Myers Squibb. Within the attached financial tables presented, certain columns and rows may not add due to the use of rounded numbers. The extension will allow sufficient time to review information pertaining to updates of the proposed Risk Evaluation Mitigation Strategy (REMS). . Stocks gain as Bostic backs quarter-point hike; Hewlett Packard Enterprise lifts annual guidance after Q1 results beat estimates; Fed wrestles whether recent data a 'blip' or a warning on inflation Diaspora holiday schedule. . They offer 3 weeks after 3 or 4 years and they go up every couple of years. The FDA has accepted the NDA and the EMA has validated the Marketing Authorization Application for deucravacitinib for the treatment of adults with moderate to severe plaque psoriasis. We believe people learn the most through on-the-job experiences. ET. After the war and into the 1960s, both Squibb and Bristol-Myers expanded their production and research of antibiotics. Bristol-Myers Squibb's revenue was $11,406 million in Q4 2022, showing mixed results compared to previous quarters, and there are many explanations for this, which will be discussed in the article . Non-GAAP EPS . Returns Risk A+ 0.4 beta (5Y monthly). I am ready to take up a new challenge and I would like to take this opportunity to put the knowledge and skills acquired during my career at the service of my new employer and future colleagues. 867 0 obj We encourage investors to review our financial statements and publicly-filed reports in their entirety and not to rely on any single financial measure. Bristol-Myers Squibb Company (BMY) NYSE - Nasdaq Real Time Price. Risk Evaluation and Mitigation Strategies (REMS), Pre-Approval Access to Investigational Medicines, Areas of Interest & Competitive Research Grants, The Thomas O. Daniel Research Incubator and Collaboration Center, Acquisition FAQs for Celgene Shareholders, Acquisition-related information for Celgene shareholders, Unsubscribe to News Email Alerts - Bristol Myers Squibb, Subscribe to New Email Alerts - Bristol Myers Squibb, BMS at June 2022 oncology and hematology congresses, Committed to creating a better future for cancer patients, People & Business Resource Groups leadership team, Our Commitment to Equal Employment Opportunity, Access to Medicines in the Developing World, Standards of Business Conduct and Ethics. We are honored to be recognized by Fortune once again as one of the Worlds Most Admired Companies. Learn about our safety approach to COVID-19 >. All comparisons are made versus the same period in 2021 unless otherwise stated. In addition, non-GAAP gross margin, which is gross profit excluding certain specified items as a percentage of revenues, non-GAAP operating margin, which is operating income excluding certain specified items as a percentage of revenues; non-GAAP free cash flow, which is non-GAAP net earnings plus adjustments related to cash generated from operating activities and cash paid for capital expenditures; non-GAAP marketing, selling and administrative expenses, which is marketing, selling and administrative expense excluding certain specified items, and non-GAAP research and development expenses, which is research and development expenses excluding certain specified items, are relevant and useful for investors because they allow investors to view performance in a manner similar to the method used by our management and make it easier for investors, analysts and peers to compare our operating performance to other companies in our industry and to compare our year-over-year results. Our expansive library of resources covers a wide range of special interest topics in multiple languages through a variety of top learning and development resources powered by LinkedIn Learning. Top 40%. Available to US-based employeesChange location. This communication contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things, the acquisition of Turning Point Therapeutics by the company and the development and commercialization of certain biological compounds. %PDF-1.5 % I'm a new hire. 0000002778 00000 n It offers chemically-synthesized drugs or. The basis for our security efforts is to protect our employees, operations and intellectual property. ***Included as part of the key loss of exclusivity (LOE) brands, *In excess of +100%. Glassdoor is your resource for information about the Paid Holidays benefits at Bristol Myers Squibb. Recently declared a week off fro everybody between xmas and new years. Meet Our Team in Tampa, FL Meet Our Team in Tampa, FL Possibility Lives at BMS Find out why possibility lives at Bristol Myers Squibb Asha on Skills 2 Give Volunteer Program Asha on Skills 2 Give Volunteer Program I am confident in our ability to execute against our key milestones in 2022, including three planned first-in-class launches with relatlimab plus nivolumab fixed dose combination, mavacamten and deucravacitinib. Similar charges or gains were recognized in prior periods and will likely reoccur in future periods. Note to new hires: Access to enrollment site will begin 3-5 days after your hire date. NEW YORK--(BUSINESS WIRE)-- Learn more about the cookies we use on our General Privacy Notice page. Case Timeline November 12, 2021 PRESS RELEASE: FTC Approves Modifications to Bristol Meyers Squibb Divestiture Agreement January 13, 2020 File Complaint (112.81 KB) File Learn about Bristol Myers Squibb Paid Holidays, including a description from the employer, and comments and ratings provided anonymously by current and former Bristol Myers Squibb employees. Learn more! All of our employees must comply with the highest standards of data privacy protection consistent with the laws of the jurisdiction in which they operate. A copy of the tender offer statement and the solicitation/recommendation statement will be made available to all stockholders of Turning Point Therapeutics free of charge at tptherapeutics.com. Bristol-Myers is Eisai Co., Ltd. and Bristol-Myers Squibb Company (NYSE: 21-04897. Marketing, selling and administrative expenses decreased 13% to $2.4 billion in the quarter primarily due to cash settlement of MyoKardia unvested stock awards in the prior year, and certain incremental and accelerated investments to support our business in 2020, partially offset by investments to support new product launches. 0000043468 00000 n endobj They merged in 1989, creating a powerhouse pharmaceutical company that was the second-largest in the world at the time. 0000012839 00000 n ET on February 18, 2022 by dialing in the U.S. toll free 888-203-1112 or international +1 719-457-0820, confirmation code: 2150568. Cautionary Statement Regarding Forward-Looking Statements. (, In November, the company presented new data from across its cardiovascular portfolio (, Phase 2 AXIOMATIC-TKR trial that showed milvexian reduced the risk of postoperative venous thromboembolism in a dose dependent manner without increasing the risk of bleeding compared with enoxaparin in patients undergoing total knee replacement surgery. Christi Shaw just announced her resignation from the position of CEO of Kite. Reconciliations of these non-GAAP financial measures to the most comparable GAAP measures for a particular quarterly period are available on the companys website at www.bms.com . Namely, we are not able to reliably predict the impact of specified items or currency exchange rates beyond the next twelve months. 11:00 am EST. Bristol Myers Squibb (NYSE:BMY) will announce results for the first quarter of 2021 on Thursday, April 29, 2021. 0000043107 00000 n Under the terms of the merger agreement, Bristol Myers Squibb will promptly commence a tender offer to acquire all of the outstanding shares of Turning Point Therapeutics common stock at a price of $76.00 per share in an all-cash transaction for a total consideration of $4.1 billion in equity value. This culture of inclusion encourages everyone to pursue innovative ideas, develop leadership capabilities and gain valuable, diverse experiences to shape exciting careers. 0000003062 00000 n Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. Your response will be removed from the review this cannot be undone. For more information, call BMS Access Support at 1-800- 861- 0048, 8 am to 8 pm ET, Monday - Friday. Similar charges or gains were recognized in prior periods and will likely reoccur in future periods, including amortization of acquired intangible assets, including product rights that generate a significant portion of our ongoing revenue and will recur until the intangible assets are fully amortized, unwind of inventory purchase price adjustments, acquisition and integration expenses, restructuring costs, accelerated depreciation and impairment of property, plant and equipment and intangible assets, R&D charges or other income resulting from up-front or contingent milestone payments in connection with the acquisition or licensing of third-party intellectual property rights, divestiture gains or losses, stock compensation resulting from accelerated vesting of Celgene awards, certain retention-related employee compensation charges related to the Celgene transaction, pension, legal and other contractual settlement charges, equity investment and contingent value rights fair value adjustments (including fair value adjustments attributed to limited partnership equity method investments beginning in 2021) and amortization of fair value adjustments of debt acquired from Celgene in our 2019 exchange offer, among other items. ET on April 29, 2021 Bristol-Myers Squibb (NYSE:BMY) SVP Adam Dubow sold 3,119 shares of the business's stock in a transaction dated Wednesday, May 5th. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.You can see all of today's research reports here >>>Bristol-Myers Squibb's shares .
